•  
  •  
  •  
  •  

2026-08-12 12:24:00

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT

Keywords Selected:  Cipla

Research

  • ICICI Direct on Cipla: Consolidation breakout signifies resumption of primary up trend...

Stock Report

  • Cipla Reports Q1 FY27 Net Profit of ₹785.55 Crore; Revenue from Operations Rises 8.8% Sequential to ₹7,119.28 Crore
  • USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA
  • USFDA inspection at Cipla Ltd's manufacturing facility in Verna, Goa, India
  • Cipla Ltd recommends final dividend of Rs. 13
  • Cipla reports consolidated PAT of Rs. 554.64 crores in Q4 FY26
  • Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA
  • USFDA inspection at Cipla Ltd's manufacturing facility in Goa, India
  • Cipla reports consolidated PAT of Rs. 675.80 crores
  • Pfizer & Cipla announce Exclusive Marketing and Distribution Partnership for Select Brands in India
  • Cipla launches Yurpeak® (tirzepatide) for the treatment of Obesity and Type 2 Diabetes
  • Cipla Launches India's First Dedicated Lung Health Diagnostics Center in Delhi
  • Cipla Ltd consolidated Q2FY26 net profit increases to Rs. 1351.17 crores
  • Lilly and Cipla sign a distribution and promotion agreement for Yurpeak® in India
  • SES ESG Research Pvt Ltd assigns ESG rating of 69.3 to Cipla Ltd
  • Cipla Ltd Q1 FY2025-26 consolidated profit up at Rs. 1297.62 crores
  • Cipla Health takes a humorous spin on real life stories with Astaberry's campaign 'Get the Rich Look'
  • Cipla Health launches a new campaign for Cipladine with Neena Gupta as brand ambassador
  • Cipla Health launches a new campaign for Cipladine with Neena Gupta as brand ambassado
  • Update on USFDA inspection at manufacturing facility of Medispray in Kundaim, Goa, India
  • Cipla Limited receives USFDA final approval for ANDA Protein-bound Paclitaxel
  • USFDA inspection at manufacturing facility of Medispray in Kundaim, Goa, India
  • Cipla Ltd's Q1FY25 consolidated net profit climbs to Rs. 1177.64 crores
  • Cipla Limited's Kurkumbh facility gets VAI classification from USFDA
  • Orchid Pharma partners with Cipla to launch antibiotic Cefepime-Enmetazobactam in India

Latest Post

  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025